Acquired somatic ATRX mutations in myelodysplastic syndrome associated with α thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations

Blood

Volumn 103, Issue 6, 2004, Pages 2019-2026

  Steensma, David P ^a   Higgs, Douglas R ^b   Fisher, Chris A ^b   Gibbons, Richard J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HEMOGLOBIN H;

ADULT; AGED; ALPHA THALASSEMIA; AMINO ACID SUBSTITUTION; ARTICLE; ATRX GENE; BLOOD; BONE MARROW; CHROMATIN; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE SEVERITY; FEMALE; GENE; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MOSAICISM; MYELODYSPLASTIC SYNDROME; PEDIGREE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; SOMATIC MUTATION;

EID: 1542283736     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-09-3360     Document Type: Article

References (43)

1. Weatherall DJ, Clegg JB. The Thalassaemic Syndromes. 4th ed. Malden, MA: Blackwell Science; 2001.
2. Bernini LF, Harteveld CL. Alpha-thalassaemia. Baillieres Clin Haematol, 1998;11: 53-90.
3. Olivieri, NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.
4. Bradley TB, Ranney HM. Acquired disorders of hemoglobin. Prog Hematol. 1973;8:77-98.
5. Wood WG. Increased HbF in adult life. Baillieres Clin Haematol. 1993;6:177-213.
6. Rochette J, Craig JE, Thein SL. Fetal hemoglobin levels in adults. Blood Rev. 1994;8:213-224.
7. Aksoy M, Erdem S. Decrease in the concentration of haemoglobin A2 during erythroleukaemia. Nature. 1967;213:522-523.
8. Weatherall DJ, Old J, Longley J, et al. Acquired haemoglobin H disease in leukemia: pathophysiology and molecular basis. Br J Haematol. 1978;38:305-322.
9. Higgs DR, Wood WG, Barton C, Weatherall DJ. Clinical features and molecular analysis of acquired hemoglobin H disease. Am J Med. 1983;75:181-191.
10. Hoyle C, Kaeda J, Leslie J, Luzzatto L. Acquired beta thalassaemia trait in MDS. Br J Haematol. 1991;79:116-117.
11. Markham RE, Butler F, Goh K, Rowley PT. Erythroleukemia manifesting delta beta-thalassemia. Hemoglobin. 1983;7:71-78.
12. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003;101:791-800.
13. Higgs DR, Vickers MA, Wilkie AO, Pretorius IM, Jarman AP, Weatherall DJ. A review of the molecular genetics of the human alpha-globin gene cluster. Blood. 1989;73:1081-1104.
14. Viprakasit V, Kidd AM, Ayyub H, Horsley S, Hughes J, Higgs DR. De novo deletion within the telomeric region flanking the human alpha globin locus as a cause of alpha thalassaemia. Br J Haematol. 2003;120:867-875.
15. Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell. 1995;80: 837-845.
16. Gibbons RJ, Pellagatti A, Garrick D, et al. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet. 2003;34:446-449.
17. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109:121-124.
18. Weatherall DJ, Clegg JB, Naughton MA. Globin synthesis in thalassaemia: an in vitro study. Nature. 1965;208:1061-1065.
19. Clegg JB, Weatherall DJ, Na-Nakorn S, Wasi P. Haemoglobin synthesis in beta-thalassaemia. Nature. 1968;220:664-668.
20. Gibbons RJ, Bachoo S, Picketts DJ, et al. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. Nat Genet. 1997;17:146-148.
21. Aasland R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci. 1995; 20:56-59.
22. Picketts DJ, Tastan AO, Higgs DR, Gibbons RJ. Comparison of the human and murine ATRX gene identifies highly conserved, functionally important domains. Mamm Genome. 1998;9:400-403.
23. Picketts DJ, Higgs DR, Bachoo S, Blake DJ, Quarrell OW, Gibbons RJ. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet. 1996;5:1899-1907.
24. Gibbons RJ, McDowell TL, Raman S, et al. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat Genet. 2000;24:368-371.
25. McDowell TL, Gibbons RJ, Sutherland H, et al. Localization of a putative transcriptional regulator (ATRX) at pericentromeric heterochromatin and the short arms of acrocentric chromosomes. Proc Natl Acad Sci U S A. 1999;96:13983-13988.
26. Berube NG, Smeenk CA, Picketts DJ. Cell cycle-dependent phosphorylation of the ATRX protein correlates with changes in nuclear matrix and chromatin association. Hum Mol Genet. 2000;9: 539-547.
27. Xue Y, Gibbons R, Yan Z, et al. The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodies. Proc Natl Acad Sci U S A. 2003;100:10635-10640.
28. Eskiw CH, Bazett-Jones DP. The promyelocytic leukemia nuclear body: sites of activity? Biochem Cell Biol. 2002;80:301-310.
29. Gibbons RJ, Brueton L, Buckle VJ, et al. Clinical and hematologic aspects of the X-linked alpha-thalassemia/mental retardation syndrome (ATRX). Am J Med Genet. 1995;55:288-299.
30. Gibbons RJ, Garrick D, Sharpe J, et al. Disruption of ATRX in mouse by conditional knockout [abstract]. Am Soc Hum Genet. Baltimore, MD; 2002:116.
31. List AF, Doll DC. The myelodysplastic syndromes. In: Lee GR, ed. Wintrobe's Clinical Hematology. 10th ed. Baltimore, MD: Lippincott, Williams & Wilkins; 1999:2320-2341.
32. Kibbelaar RE, van Kamp H, Dreef EJ, et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood. 1992;79:1823-1828.
33. van Kamp H, Fibbe WE, Jansen RP, et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood. 1992;80:1774-1780.
34. Asano H, Ohashi H, Ichihara M, et al. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes. Blood. 1994;84:588-594.
35. Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol. 2001;73: 411-415.
36. Levin BC, Tully LA, Hancock DK, Schwarz FP, Lee MS. A new NIST mitochondrial DNA interactive website. MitoMatters. 2002;1:5-6.
37. Borgione E, Sturnio M, Spalletta A, et al. Mutational analysis of the ATRX gene by DGGE: a powerful diagnostic approach for the ATRX syndrome. Hum Mutat. 2003;21:529-534.
38. Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res. 1998;26:1396-1400.
39. Emmerson P, Maynard J, Jones S, Butler R, Sampson JR, Cheadle JP. Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat. 2003;21:112-115.
40. Jones AC, Sampson JR, Cheadle JP. Low level mosaicism detectable by DHPLC but not by direct sequencing. Hum Mutat. 2001;17:233-234.
41. van Den Bosch BJ, de Coo RF, Scholte HR, et al. Mutation analysis of the entire mitochondrial genome using denaturing high performance liquid chromatography. Nucleic Acids Res. 2000;28: E89.
42. Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjlan HM. Acute myeloid leukemia. American Society of Hematology Education Book. 2002:73-110.
43. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol. 2001;73:429-437.